JAK-IN-11

• UNSPSC Description:

  JAK-IN-11 is a potent and selective JAK inhibitor extracted from patent WO2012122452A1, Compound II, has the potential for the skin disorders (such as cutaneous lupus) treatment[1]. JAK-IN-11 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

• Target Antigen:

  JAK

• Type:

  Reference compound

• Related Pathways:

  Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/Propanamide,_N-[[5-[[5-fluoro-4-[[4-_2-propyn-1-yloxy_phenyl]amino]-2-pyrimidinyl]amino]-2-methylphenyl]sulfonyl]-.html

• Purity:

  98.62

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  C#CCOC1=CC=C(NC2=NC(NC3=CC=C(C)C(S(=O)(NC(CC)=O)=O)=C3)=NC=C2F)C=C1

• Molecular Weight:

  483.52

• References & Citations:

  [1]Daniel Magilavy, et al. 2,4 substituted pyrimidinediamines for use in discoid lupus. WO2012122452A1.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, stored under nitrogen)

• Clinical Information:

  No Development Reported

• CAS Number:

  916742-11-5